CASI Pharmaceuticals Shares Are Trading Higher After the Company Announced Plans to Submit an Investigational New Drug Application to the FDA for CID-103 for the Treatment of Antibody-mediated Rejection in Kidney Transplant Recipients. Also, the...
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.